Genentech (@genentech) / X

Genentech

7,804 posts

Genentech

@genentech

Official Twitter for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz

USA

gene.com

Joined September 2008

Genentech
@genentech
Jun 2
#Breaking: @US_FDA accepted the New Drug Application, under Priority Review, for our investigational oral selective estrogen receptor degrader (SERD) as a treatment for adults with ER+, HER2-, early-stage breast cancer. Learn more: gene.com/media/press-re…
00:00
1.6K
Genentech
@genentech
Jun 1
#Breaking: We are presenting data at the upcoming #ADASciSessions from our obesity portfolio, highlighting our differentiated approaches to addressing unmet needs for people living with #obesity. Learn more: gene.com/media/press-re…
00:00
1.4K
Genentech
@genentech
May 19
#Breaking: We’re presenting new data across breast, lung, gastrointestinal, bladder and blood cancers at the American Society of Clinical Oncology (#ASCO26). Learn more about our efforts to transform cancer care: gene.com/media/press-re…
00:00
1.9K
Genentech
@genentech
May 15
#Breaking: @US_FDA approved our immunotherapy as an adjuvant treatment option for adults with muscle-invasive bladder cancer (#MIBC) after surgery (cystectomy) who have circulating tumor DNA (ctDNA) molecular residual disease. Learn more: gene.com/media/press-re…
00:00
2K
Genentech
@genentech
Apr 30
At the Association for Research in Vision and Ophthalmology Annual Meeting, we’re sharing key real-world, product and pipeline data from our ophthalmology portfolio. Learn more: gene.com/media/press-re… #ARVO2026
1.2K
Genentech
@genentech
Apr 24
Launching today, All Eyes on DME is our new campaign highlighting diabetic macular edema (DME), an often overlooked eye condition linked to diabetes. Learn more: gene.com/media/press-re…
00:00
1.1K
Genentech
@genentech
Apr 21
#Breaking: At the 2026 AAN Annual Meeting (#AANAM), we unveiled positive comprehensive results from our Phase III trials evaluating our investigational BTK inhibitor (BTKi) in people living with relapsing multiple sclerosis (RMS). Learn more:
gene.com
Genentech: Press Releases | Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard...
Discover the latest news about our company, our products, our policies, and our people.
1.2K
Genentech
@genentech
Apr 21
#Breaking: At #AANAM, we announced positive results from our Phase III study in myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Learn more: gene.com/media/press-re…
1.3K
Genentech
@genentech
Apr 21
#Breaking: The @US_FDA accepted our supplemental Biologics License Application for our medicine to treat systemic lupus erythematosus (SLE), the most common form of #lupus, based on positive Phase III data. If approved, it would be the first therapy to directly target B cells in
00:00
1.9K
Genentech
@genentech
Mar 6
#Breaking: Today meaningful data from our Phase III study in systemic lupus erythematosus was published in @NEJM. Learn more: gene.com/media/press-re…
00:00
2.5K
Genentech
@genentech
Mar 5
#Breaking: Positive Phase II results for our investigational long‑acting amylin analog with Zealand Pharma mark an important step forward as we move from a one‑size‑fits‑all approach to more tailored options for people living with #obesity. gene.com/media/press-re…
00:00
1.9K
Genentech
@genentech
Mar 2
#Breaking: Today we announced positive additional Phase III clinical results of our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…
1.8K
Genentech
@genentech
Feb 20
#Breaking: @US_FDA approved our new combination regimen as the first and only all-oral, fixed-duration treatment for previously untreated adults with chronic lymphocytic leukemia (CLL). Learn more: gene.com/media/press-re…
00:00
1.8K